

NCT01313676 Raw comparison:

Summary:
CHIA has 31 criteria while your personal folder has 33 criteria
Total found criteria: 31/31
Total not Found: 0/31
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Type of subject outpatient                         │ Type of subject outpatient                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Informed consent Subjects must give their signed   │ Informed consent Subjects must give their signed   │
│ and dated written informed consent to participate  │ and dated written informed consent to participate  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Gender Male or female Female subjects must be      │ Gender Male or female Female subjects must be      │
│ post-menopausal or using a highly effective method │ post-menopausal or using a highly effective method │
│ for avoidance of pregnancy The decision to include │ for avoidance of pregnancy The decision to include │
│ or exclude women of childbearing potential may be  │ or exclude women of childbearing potential may be  │
│ made at the discretion of the investigator in      │ made at the discretion of the investigator in      │
│ accordance with local practice in relation to      │ accordance with local practice in relation to      │
│ adequate contraception                             │ adequate contraception                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age >=40 and <=80 years of age at Screening (Visit │ Age \>=40 and \<=80 years of age at Screening      │
│ 1)                                                 │ (Visit 1)                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Tobacco use Subjects with a current or prior       │ Tobacco use Subjects with a current or prior       │
│ history of >=10 pack-years of cigarette smoking at │ history of \>=10 pack-years of cigarette smoking   │
│ screening (Visit 1) Previous smokers are defined   │ at screening (Visit 1) Previous smokers are        │
│ as those who have stopped smoking for at least 6   │ defined as those who have stopped smoking for at   │
│ months prior to Visit 1                            │ least 6 months prior to Visit 1                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Airflow Obstruction                                │ Airflow Obstruction                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with a measured post-albuterol/salbutamol │ Subjects with a measured post-albuterol/salbutamol │
│ forced expiratory volume in 1 second               │ forced expiratory volume in 1 second               │
│ (FEV1)/(forced vital capacity)FVC ratio of <=0 70  │ (FEV1)/(forced vital capacity)FVC ratio of \<=0 70 │
│ at Screening (Visit 1)                             │ at Screening (Visit 1)                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with a measured post-albuterol/salbutamol │ Subjects with a measured post-albuterol/salbutamol │
│ FEV1 >=50 and <=70% of predicted normal values     │ FEV1 \>=50 and \<=70% of predicted normal values   │
│ calculated using NHANES III reference equations    │ calculated using NHANES III reference equations    │
│ [Hankinson 1999 Hankinson 2010] at Screening       │ \[Hankinson 1999 Hankinson 2010\] at Screening     │
│ (Visit 1)                                          │ (Visit 1)                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Post-bronchodilator spirometry will be performed   │ Post-bronchodilator spirometry will be performed   │
│ approximately 15 minutes after the subject has     │ approximately 15 minutes after the subject has     │
│ self-administered 4 inhalations (i e total 400mcg) │ self-administered 4 inhalations (i e total 400mcg) │
│ of albuterol/salbutamol via a metered dose inhaler │ of albuterol/salbutamol via a metered dose inhaler │
│ (MDI )with a valved-holding chamber The FEV1/FVC   │ (MDI )with a valved-holding chamber The FEV1/FVC   │
│ ratio and FEV1 percent predicted values will be    │ ratio and FEV1 percent predicted values will be    │
│ calculated                                         │ calculated                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Symptoms of COPD Subjects must score 2 or higher   │ Symptoms of COPD Subjects must score 2 or higher   │
│ on the modified Medical Research Council Dyspnea   │ on the modified Medical Research Council Dyspnea   │
│ scale (Visit 1)                                    │ scale (Visit 1)                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Cardiovascular disease                             │ Cardiovascular disease                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ For patients >= 40 years of age any one of the     │ For patients \>= 40 years of age any one of the    │
│ following                                          │ following                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Established (i e by clinical signs or imaging      │ Established (i e by clinical signs or imaging      │
│ studies) coronary artery disease (CAD) Established │ studies) coronary artery disease (CAD) Established │
│ (i e by clinical signs or imaging studies)         │ (i e by clinical signs or imaging studies)         │
│ peripheral vascular disease (PVD) Previous stroke  │ peripheral vascular disease (PVD) Previous stroke  │
│ Previous MI Diabetes mellitus with target organ    │ Previous MI Diabetes mellitus with target organ    │
│ disease OR                                         │ disease OR                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ For patients >=60 years of age any 2 of the        │ For patients \>=60 years of age any 2 of the       │
│ following                                          │ following                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Being treated for hypercholesterolemia Being       │ Being treated for hypercholesterolemia Being       │
│ treated for hypertension Being treated for         │ treated for hypertension Being treated for         │
│ diabetes mellitus Being treated for peripheral     │ diabetes mellitus Being treated for peripheral     │
│ vascular disease                                   │ vascular disease                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnancy Women who are pregnant or lactating      │ Pregnancy Women who are pregnant or lactating      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Asthma Subjects with a current diagnosis of asthma │ Asthma Subjects with a current diagnosis of asthma │
│ (Subjects with a prior history of asthma are       │ (Subjects with a prior history of asthma are       │
│ eligible if they also have a current diagnosis of  │ eligible if they also have a current diagnosis of  │
│ COPD)                                              │ COPD)                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ alpha 1-antitrypsin deficiency Subjects with known │ alpha 1-antitrypsin deficiency Subjects with known │
│ alpha-1 antitrypsin deficiency as the underlying   │ alpha-1 antitrypsin deficiency as the underlying   │
│ cause of COPD                                      │ cause of COPD                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other respiratory disorders Subjects with active   │ Other respiratory disorders Subjects with active   │
│ tuberculosis lung cancer bronchiectasis            │ tuberculosis lung cancer bronchiectasis            │
│ sarcoidosis pulmonary fibrosis pulmonary           │ sarcoidosis pulmonary fibrosis pulmonary           │
│ hypertension interstitial lung diseases or other   │ hypertension interstitial lung diseases or other   │
│ active pulmonary diseases                          │ active pulmonary diseases                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Lung resection or transplantation Subjects with    │ Lung resection or transplantation Subjects with    │
│ lung volume reduction surgery within the 12 months │ lung volume reduction surgery within the 12 months │
│ prior to Screening or having had a lung transplant │ prior to Screening or having had a lung transplant │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A moderate/severe COPD exacerbation that has not   │ A moderate/severe COPD exacerbation that has not   │
│ resolved at least 14 days prior to Visit 1 and at  │ resolved at least 14 days prior to Visit 1 and at  │
│ least 30 days following the last dose of oral      │ least 30 days following the last dose of oral      │
│ corticosteroids (if applicable)                    │ corticosteroids (if applicable)                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current severe heart failure (New York Heart       │ Current severe heart failure (New York Heart       │
│ Association class IV) Subjects will also be        │ Association class IV) Subjects will also be        │
│ excluded if they have a known ejection fraction of │ excluded if they have a known ejection fraction of │
│ <30% or if they have an implantable cardioverter   │ \<30% or if they have an implantable cardioverter  │
│ defibrillator (ICD)                                │ defibrillator (ICD)                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other diseases/abnormalities Any life-threatening  │ Other diseases/abnormalities Any life-threatening  │
│ condition with life expectancy <3 years other than │ condition with life expectancy \<3 years other     │
│ vascular disease or COPD that might prevent the    │ than vascular disease or COPD that might prevent   │
│ subject from completing the study                  │ the subject from completing the study              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ End stage chronic renal disease Subjects will be   │ End stage chronic renal disease Subjects will be   │
│ excluded if on renal replacement therapy           │ excluded if on renal replacement therapy           │
│ (hemodialysis or peritoneal)                       │ (hemodialysis or peritoneal)                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Drug/food allergy Subjects with a history of       │ Drug/food allergy Subjects with a history of       │
│ hypersensitivity to any of the study medications   │ hypersensitivity to any of the study medications   │
│ (e g beta-agonists corticosteroid) or components   │ (e g beta-agonists corticosteroid) or components   │
│ of the inhalation powder (e g lactose magnesium    │ of the inhalation powder (e g lactose magnesium    │
│ stearate) In addition patients with a history of   │ stearate) In addition patients with a history of   │
│ severe milk protein allergy that in the opinion of │ severe milk protein allergy that in the opinion of │
│ the study physician contraindicates the subject's  │ the study physician contraindicates the subject's  │
│ participation will also be excluded                │ participation will also be excluded                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Drug/alcohol abuse Subjects with a known or        │ Drug/alcohol abuse Subjects with a known or        │
│ suspected history of alcohol or drug abuse within  │ suspected history of alcohol or drug abuse within  │
│ the last 2 years                                   │ the last 2 years                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Oxygen therapy Subjects receiving treatment with   │ Oxygen therapy Subjects receiving treatment with   │
│ long-term oxygen therapy (LTOT) or nocturnal       │ long-term oxygen therapy (LTOT) or nocturnal       │
│ oxygen therapy required for greater than 12 hours  │ oxygen therapy required for greater than 12 hours  │
│ a day Oxygen prn use (i e <=12 hours per day) is   │ a day Oxygen prn use (i e \<=12 hours per day) is  │
│ not exclusionary                                   │ not exclusionary                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Questionable validity of consent Subjects with a   │ Questionable validity of consent Subjects with a   │
│ history of psychiatric disease intellectual        │ history of psychiatric disease intellectual        │
│ deficiency poor motivation or other conditions     │ deficiency poor motivation or other conditions     │
│ that will limit the validity of informed consent   │ that will limit the validity of informed consent   │
│ to participate in the study or the potential       │ to participate in the study or the potential       │
│ compliance to study procedures                     │ compliance to study procedures                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Affiliation with investigator site Study           │ Affiliation with investigator site Study           │
│ investigators sub-investigators study coordinators │ investigators sub-investigators study coordinators │
│ employees of a participating investigator or       │ employees of a participating investigator or       │
│ immediate family members of the aforementioned are │ immediate family members of the aforementioned are │
│ excluded from participating in this study          │ excluded from participating in this study          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Additional medication Use of the following         │ Additional medication Use of the following         │
│ medications within the following time intervals    │ medications within the following time intervals    │
│ prior to Visit 1 or during the study (unless       │ prior to Visit 1 or during the study (unless       │
│ otherwise specified)                               │ otherwise specified)                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Medication No use within the following time        │ Medication No use within the following time        │
│ intervals prior to Screening or thereafter at any  │ intervals prior to Screening or thereafter at any  │
│ time during the study (unless otherwise specified) │ time during the study (unless otherwise specified) │
│ Inhaled Long acting beta-agonists (LABA) 48 hours  │ Inhaled Long acting beta-agonists (LABA) 48 hours  │
│ ICS/LABA combination products 48 hours Inhaled     │ ICS/LABA combination products 48 hours Inhaled     │
│ corticosteroids 48 hours Tiotropium 1 week         │ corticosteroids 48 hours Tiotropium 1 week         │
│ Systemic Oral parenteral intra-articular           │ Systemic Oral parenteral intra-articular           │
│ corticosteroids 30 days (oral and systemic         │ corticosteroids 30 days (oral and systemic         │
│ corticosteroids may be used to treat COPD          │ corticosteroids may be used to treat COPD          │
│ exacerbations during the study) Cytochrome P450    │ exacerbations during the study) Cytochrome P450    │
│ 3A4 strong inhibitors including but not limited to │ 3A4 strong inhibitors including but not limited to │
│ antiretrovirals (protease inhibitors) (e g         │ antiretrovirals (protease inhibitors) (e g         │
│ Indinavir Nelfinavir Ritonavir Saquinavir)         │ Indinavir Nelfinavir Ritonavir Saquinavir)         │
│ Imidazole and Triazole anti-fungals (e g           │ Imidazole and Triazole anti-fungals (e g           │
│ Ketaconazole Itraconazole) Clarithromycin          │ Ketaconazole Itraconazole) Clarithromycin          │
│ Telithromycin Amiodarone and Nefazodone 6 weeks    │ Telithromycin Amiodarone and Nefazodone 6 weeks    │
│ Grapefruit is allowed up to Visit 1 then limited   │ Grapefruit is allowed up to Visit 1 then limited   │
│ to no more than one glass of grapefruit juice (250 │ to no more than one glass of grapefruit juice (250 │
│ mL/ 8 ounces) or one grapefruit per day Any other  │ mL/ 8 ounces) or one grapefruit per day Any other  │
│ investigational drug 30 days or 5 half lives       │ investigational drug 30 days or 5 half lives       │
│ whichever is longer                                │ whichever is longer                                │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 40 Years │
├───────────────────────────────────┤
│ Must have maximum age of 80 Years │
╘═══════════════════════════════════╛